Character Strengths-Based Intervention for Enhancing Self-esteem and Quality of Life and Alleviating Depression in Female Patients With Breast Cancer: A Randomized Controlled Trial.

Cancer NursMar 24, 2025 (epub)

Tingting Yan, Ka Ming Chow, Jannan Xiao et al.

✦ AI-curated · Sources linked

In 30 seconds

This multisite, assessor-blinded randomized controlled trial evaluated a culturally tailored character strengths-based intervention (CSI) in Chinese female patients with breast cancer. Participants were assigned to CSI or an “early memories” control program, with outcomes assessed at baseline, immediately after the intervention, and 1 month later. Compared with the control group, CSI significantly increased self-esteem and quality of life and reduced depressive symptoms at both postintervention assessments. Interviews with participants in the CSI group also explored acceptability, perceived benefits, implementation facilitators and barriers, and recommendations.

Key findings

  • Among 122 participants, 61 were assigned to CSI and 61 to the “early memories” control program.
  • CSI significantly increased self-esteem and quality of life at both immediately postintervention and 1 month postintervention.
  • Depressive symptoms were significantly reduced in the CSI group at both postintervention assessments.
  • Interviews identified themes concerning acceptability, perceived benefits, implementation facilitators and barriers, and recommendations.

Why it matters

Self-esteem, quality of life, and depressive symptoms are relevant dimensions of wellbeing for people with breast cancer. This trial provides evidence that a culturally tailored strengths-based program may improve these outcomes over the short term, while participant interviews offer insight into how the intervention was experienced and what may support its delivery.

What to keep in mind

Follow-up was limited to 1 month after the intervention, so the abstract does not establish whether benefits persist longer term.

Source

Published in Cancer Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.